Dernières nouvelles pour FIGS (NYSE:FIGS) Stock

FIGS INC-CLASS A

FIGS

FIGS Inc is a healthcare apparel company. The Company designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear and other apparel. The Company generates maximum revenue from United States. Sales are generated through the Company's digital platforms.

FIGS Inc

<a href="https://www.bloomberg.com/news/articles/2025-06-05/openai-and-benchmark-are-backing-new-startups-from-ex-openai-staffers?srnd=homepage-americas" title="https://www.bloomberg.com/news/articles/2025-06-05/openai-and-benchmark-are-backing-new-startups-from-ex-openai-staffers?srnd=homepage-americas">https://www.bloomberg.com/news/articles/2025-06-05/openai-and-benchmark-are-backing-new-startups-from-ex-openai-staffers?srnd=homepage-americas</a>

News

MSFT

'OpenAI and Benchmark Back New Startups From Ex-OpenAI Staffers' - Bloomberg News

Macro Economic Events

Economics

Markets

Texas Stock Exchange CEO Reportedly Says It Costs Too Much For Companies To Go Public And To Remain Public; Says 35% Of Existing U.S.-Listed Public Companies Would Be Ineligible For Texas Listing; Says Chinese Cos That Do Not Meet The Basic U.S. Listing Standards Will Not Be Listed On The Exchange; Says Most New Primary Listings Will Come From Small, Mid-Cap Firms

WIIM

Argan shares are trading higher after Lake Street raised its price target on the stock from $150 to $236.

ARLO

Arlo Technologies shares are trading higher after the company announced it has surpassed the $300 million annual recurring revenue milestone.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Wedbush analyst David Nierengarten initiated coverage on Telix Pharmaceuticals Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLX#NASDAQ">TLX</a>) with an Outperform rating and announced a price target of $22. Telix Pharmaceuticals shares closed at $17.48 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Emma Schwartz initiated coverage on Excelerate Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EE#NYSE">EE</a>) with a Buy rating and announced a price target of $39. Excelerate Energy shares closed at $29.69 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Craig-Hallum analyst Albert Lowe initiated coverage on Atossa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) with a Buy rating and announced a price target of $4. Atossa Therapeutics shares closed at $0.8571 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Joshua Pokrzywinski initiated coverage on Parker-Hannifin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>) with an Equal-Weight rating and announced a price target of $700. Parker Hannifin shares closed at $665.26 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Roth Capital analyst Boobalan Pachaiyappan initiated coverage on PolyPid Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPD#NASDAQ">PYPD</a>) with a Buy rating and announced a price target of $9. PolyPid shares closed at $2.98 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying EE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="580" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05151612/image-71-1024x580.png" alt="" class="wp-image-940280" style="width:603px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05151612/image-71-1024x580.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05151612/image-71-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05151612/image-71-768x435.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05151612/image-71.png 1122w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45790405/top-2-defensive-stocks-that-are-ticking-portfolio-bombs">Top 2 Defensive Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Initiation

Analyst Ratings

Trading Ideas

ATOS

PYPD

This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

<a href="https://www.fda.gov/medical-devices/medical-device-recalls/flexible-tracheostomy-tube-recall-medtronic-removes-shiley-adult-flexible-tracheostomy-tube#:~:text=Medtronic%20and%20its%20subsidiary%20Covidien,the%20securement%20flange%20becomes%20disconnected" title="https://www.fda.gov/medical-devices/medical-device-recalls/flexible-tracheostomy-tube-recall-medtronic-removes-shiley-adult-flexible-tracheostomy-tube#:~:text=Medtronic%20and%20its%20subsidiary%20Covidien,the%20securement%20flange%20becomes%20disconnected">https://www.fda.gov/medical-devices/medical-device-recalls/flexible-tracheostomy-tube-recall-medtronic-removes-shiley-adult-flexible-tracheostomy-tube#:~:text=Medtronic%20and%20its%20subsidiary%20Covidien,the%20securement%20flange%20becomes%20disconnected</a>.

Biotech

General

'Flexible Tracheostomy Tube Recall: Medtronic Removes Shiley Adult Flexible Tracheostomy Tube with TaperGuard Cuff Reusable Inner Cannula Due to Risk for Disconnection of the Flange from the Device Cannula' - FDA

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Jefferies analyst Julien Dumoulin-Smith upgraded the rating for The Southern Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>) from Hold to Buy and lowered the price target from $102 to $100. Southern shares closed at $88.29 on Wednesday. <a href="https://www.benzinga.com/quote/SO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Matthew Boss upgraded Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) from Neutral to Overweight and raised the price target from $72 to $111. Dollar Tree shares closed at $88.62 on Wednesday. <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Janney Montgomery Scott analyst Timothy Coffey upgraded the rating for Glacier Bancorp, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBCI#NYSE">GBCI</a>) from Neutral to Buy and announced a $48 price target. Glacier Bancorp shares closed at $41.21 on Wednesday. <a href="https://www.benzinga.com/quote/GBCI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Josh Baer upgraded Udemy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UDMY#NASDAQ">UDMY</a>) from Underweight to Equal-Weight and boosted the price target from $7 to $9. Udemy shares closed at $7.69 on Wednesday. <a href="https://www.benzinga.com/quote/UDMY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho analyst Dan Dolev upgraded Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) from Neutral to Outperform and raised the price target from $359 to $425. Visa shares closed at $368.08 on Wednesday. <a href="https://www.benzinga.com/quote/V/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying Visa stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/V/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="591" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05150824/image-70-1024x591.png" alt="" class="wp-image-940262" style="width:629px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05150824/image-70-1024x591.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05150824/image-70-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05150824/image-70-768x443.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05150824/image-70.png 1113w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45790405/top-2-defensive-stocks-that-are-ticking-portfolio-bombs">Top 2 Defensive Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

Upgrades

Intraday Update

DLTR

GBCI

UDMY

This Visa Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Valneva SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>) on Thursday announced six-month antibody persistence and safety data for its Phase 2 trial evaluating the safety and immunogenicity of two different dose levels of its single-shot <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">chikungunya vaccine</a>, Ixchiq, in 304 children, according to a press release. 
Partially funded by the Coalition for Epidemic Preparedness Innovations (CEPI), with support from the European Union, the trial is intended to support a pivotal Phase 3 study in children, which the company expects to initiate in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45797405/valneva-reports-positive-six-month-antibody-persistence-and-safety-phase-2-results-in-children-for" rel="noreferrer noopener">first quarter of 2026</a>.
The objective is to extend the product label to this age group.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45356303/us-health-agencies-recommend-pausing-valnevas-chikungunya-vaccine-for-older-adults-after-adverse-events" rel="noreferrer noopener">US Health Agencies Recommend Pausing Valneva&#8217;s Chikungunya Vaccine For Older Adults After Adverse Events</a>
Trial VLA1553-221&#8217;s six-month results were in line with the initial data the company reported for this trial in January 2025.
A full dose (licensed Ixchiq formulation and presentation) elicited a more robust immune response in children aged one to eleven years at Day 15 and Day 180 post-vaccination compared to a half dose.
Overall, the immunological response profile was in line with what was previously observed <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43102451/valneva-chikungunya-vaccine-shows-high-sustained-immune-response-in-adolescents-one-year-after-single-shot" rel="noreferrer noopener">in adults and adolescents</a>.
The strong immune response was confirmed in CHIKV-naïve children with a 96.5% seroresponse rate (full dose) at Day 180.
VLA1553 was well tolerated in children aged one to 11 years, regardless of the dose or previous CHIKV infection. No safety concerns were identified.
The comparability of the VLA1553 doses tested in terms of safety and tolerability, along with the more pronounced immune response of the full dose observed for all age groups tested in children up to Day 180 post-vaccination, support the selection of the full dose for use in this population.
Juan Carlos Jaramillo, chief medical officer of Valneva, said, &#8220;The six months persistence and safety data in children are aligned with the robust antibody response and safety profile we reported in adolescents after a single vaccination.&#8221;
In April, the Brazilian Health Regulatory Agency (ANVISA) granted marketing authorization to&nbsp;Valneva&#8217;s Ixchiq&nbsp;to prevent disease caused by the chikungunya virus in <a href="https://www.benzinga.com/general/biotech/25/04/44798557/brazil-approves-valnevas-mosquito-borne-chikungunya-vaccine" target="_blank" rel="noreferrer noopener">individuals&nbsp;18 and older</a>.
The ANVISA decision marks the world's first approval of a chikungunya vaccine in an endemic country.
VALN Price Action: VALN stock is up 0.49% at $6.28 at publication on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45790700/honeywells-saf-alliance-targets-massive-renewable-output-to-power-100000-homes" target="_blank" rel="noreferrer noopener">Honeywell&#8217;s SAF Alliance Targets Massive Renewable Output To Power 100,000 Homes</a></li>
</ul>
Photo: Shutterstock

Health Care

Global

VALN

Valneva's Chikungunya Vaccine Advances With Pediatric Trial, Phase 3 In 2026

<a href="https://www.fda.gov/medical-devices/medical-device-recalls/infusion-pump-correction-baxter-issues-correction-novum-iq-large-volume-pump-due-potential#:~:text=Medical%20Device%20Recalls-,Infusion%20Pump%20Correction%3A%20Baxter%20Issues%20Correction%20for%20Novum%20IQ%20Large,due%20to%20Potential%20for%20Underinfusion&amp;text=This%20recall%20involves%20correcting%20certain,as%20the%20most%20serious%20type" title="https://www.fda.gov/medical-devices/medical-device-recalls/infusion-pump-correction-baxter-issues-correction-novum-iq-large-volume-pump-due-potential#:~:text=Medical%20Device%20Recalls-,Infusion%20Pump%20Correction%3A%20Baxter%20Issues%20Correction%20for%20Novum%20IQ%20Large,due%20to%20Potential%20for%20Underinfusion&amp;text=This%20recall%20involves%20correcting%20certain,as%20the%20most%20serious%20type">https://www.fda.gov/medical-devices/medical-device-recalls/infusion-pump-correction-baxter-issues-correction-novum-iq-large-volume-pump-due-potential#:~:text=Medical%20Device%20Recalls-,Infusion%20Pump%20Correction%3A%20Baxter%20Issues%20Correction%20for%20Novum%20IQ%20Large,due%20to%20Potential%20for%20Underinfusion&amp;text=This%20recall%20involves%20correcting%20certain,as%20the%20most%20serious%20type</a>.

'Infusion Pump Correction: Baxter Issues Correction for Novum IQ Large Volume Pump due to Potential for Underinfusion' - FDA

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rally in 2025 has been nothing short of stratospheric, with <a href="https://www.benzinga.com/crypto">the flagship crypto</a> blowing past the $100,000 mark and dreams of $200,000 swirling in the digital air. 
While bulls are eyeing the moon, two publicly traded names &#8211; MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) and Coinbase Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) &#8211; are catching serious wind from the crypto updraft. But can they stay aloft, or are they flying too close to the sun?
<h2 class="wp-block-heading">MicroStrategy: Saylor's Billion-Dollar Crypto Binge</h2>
Michael Saylor has turned MicroStrategy from a business intelligence firm into a full-throttle Bitcoin proxy. With a stash of 580,250 BTC now worth $40.6 billion, the company's fate is fused to the price of Bitcoin. The latest move? 
A cool $427 million plowed into 4,020 more coins at $106,000 each. Forget quarterly reports &#8211; MSTR&#8217;s main KPI is BTC/USD.
The math is as wild as the strategy: if Bitcoin hits $150,000, MSTR could touch $2,000 per share. At $200,000? Expect targets of $3,500 and a Saylor victory lap. But there's turbulence too. 
When BTC dipped in late 2024, MSTR shed 30% in days. With short interest ballooning past $10 billion and critics warning the market cap now dwarfs Coinbase despite a fraction of its revenue, the stock looks less like a rocket and more like a loaded powder keg.
Read Also: <a href="https://www.benzinga.com/markets/offerings/25/06/45785682/chamath-palihapitiya-says-circle-ipo-valued-at-7-billion-means-its-a-genius-buy-for-coinbase-heres-why" target="_blank" rel="noreferrer noopener">Chamath Palihapitiya Says Circle IPO Valued At $7 Billion Means It&#8217;s A &#8216;Genius&#8217; Buy For Coinbase, Here&#8217;s Why</a>
<h2 class="wp-block-heading">Coinbase: The Middleman Minting Money</h2>
Coinbase, on the other hand, is the infrastructure play &#8211; less glam, more grit. It isn't chasing Bitcoin highs with treasury funds, but instead cashing in on trading fees, ETF custodianship, and its expanding Base blockchain. It's the backstage pass to the crypto show.
When Trump's pro-crypto win sent BTC flying, COIN popped 36%. A modest January bump followed Bitcoin's 2% move. Analysts like the stability. With a <a href="https://www.benzinga.com/quote/COIN/analyst-ratings">consensus Buy rating</a> and growing ETF ties &#8211; $15 billion AUM inflows and counting &#8211; Coinbase is well-positioned for the long haul. Its $1 billion buyback announced last year is a cherry on top.
Still, Coinbase&#8217;s minimal Bitcoin holdings draw jabs from purists. But while MicroStrategy swings for home runs, Coinbase is playing the long game &#8211; consistent, diversified, and quietly raking in the chips.
<h2 class="wp-block-heading">Final Byte</h2>
Bitcoin's surge is minting winners &#8211; and MicroStrategy and Coinbase are riding different boards on the same crypto wave. 
One's a high-wire act with billions in BTC on the line. The other? A steady surfboarder cashing in on every wave.
Whether Bitcoin touches $200,000 or hits an air pocket, these two remain at the epicenter of crypto's most electrifying moment.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45798988/could-bitcoin-plummet-to-90000-soon">Could Bitcoin Plummet To $90,000 Soon?</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Long Ideas

$BTC

COIN

MSTR

Bitcoin's Moonshot: Can MicroStrategy And Coinbase Keep Riding The Crypto Wave?

<a href="https://www.wsj.com/politics/policy/senate-republicans-seek-to-protect-nasa-programs-targeted-for-cuts-d7cc4415" title="https://www.wsj.com/politics/policy/senate-republicans-seek-to-protect-nasa-programs-targeted-for-cuts-d7cc4415">https://www.wsj.com/politics/policy/senate-republicans-seek-to-protect-nasa-programs-targeted-for-cuts-d7cc4415</a>

Politics

'Senate Republicans Seek to Protect NASA Programs Targeted for Cuts' - WSJ

Costco Wholesale Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) shares are trading lower Thursday after the company released <a href="https://www.benzinga.com/pressreleases/25/06/g45780640/costco-wholesale-corporation-reports-may-sales-results">its May sales report</a>.
What To Know: For the four-week period ending June 1, 2025, Costco reported net sales of $20.97 billion, up 6.8% from $19.64 billion a year earlier. For the first 39 weeks of the fiscal year, total net sales reached $201.02 billion, an 8% increase compared to $186.07 billion last year.
Comparable sales rose 4.3% for May across the company. In the U.S., comparable sales were up just 4.1%, while international markets like Canada and other regions rose 3.3% and 6.6%, respectively. E-commerce continued to show stronger growth, up 11.6% for the month.
Stripping out the effects of gasoline prices and foreign exchange, comparable sales were stronger, 6% for the total company, including 5.5% in the U.S. and 12% in e-commerce. However, even those numbers didn't prevent the stock from falling sharply.
One reason for the selloff may be that U.S. same-store sales growth, while positive, lagged behind inflation and didn&#8217;t show a major acceleration. Gross margin and membership revenue details weren't included in the May report, leaving gaps in the picture of overall profitability and operational efficiency. Inventory and cost pressures, common issues in the retail sector, may also be on investors&#8217; minds.
Costco's sharp drop in share price suggests the market may have been expecting more aggressive growth, especially given the stock's high valuation. Despite strong year-to-date performance, the nearly 4% decline indicates that investors are looking beyond top-line growth and focusing on margin trends, U.S. consumer demand and the broader retail environment.
COST Price Action: Costco shares were down 4.01% at $1009.47 at the time of writing, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/market-summary/25/06/45798808/trump-announces-china-trade-talks-tesla-stock-slumps-whats-driving-markets-thursday">Trump Announces China Trade Talks, Tesla Stock Slumps: What&#8217;s Driving Markets Thursday? </a></li>
</ul>
Image Via Shutterstock.

Movers

COST

Costco Stock Falls Nearly 4% After May Sales Report Despite Solid Growth

Investors with a lot of money to spend have taken a bearish stance on Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AXON, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for Axon Enterprise.
This isn't normal.
The overall sentiment of these big-money traders is split between 25% bullish and 37%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $62,160, and 7, calls, for a total amount of $839,022.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $350.0 and $920.0 for Axon Enterprise, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Axon Enterprise's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Axon Enterprise's whale activity within a strike price range from $350.0 to $920.0 in the last 30 days. 
<h3>Axon Enterprise Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749150192_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$44.9</td>
<td>$42.0</td>
<td>$42.0</td>
<td>$750.00</td>
<td>$504.0K</td>
<td align="right">467</td>
<td align="right">121</td>
</tr>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$43.0</td>
<td>$41.7</td>
<td>$42.0</td>
<td>$750.00</td>
<td>$126.0K</td>
<td align="right">467</td>
<td align="right">151</td>
</tr>
<tr>
<td>AXON</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$212.0</td>
<td>$207.2</td>
<td>$207.2</td>
<td>$920.00</td>
<td>$62.1K</td>
<td align="right">1</td>
<td align="right">3</td>
</tr>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$107.8</td>
<td>$104.8</td>
<td>$107.8</td>
<td>$730.00</td>
<td>$53.9K</td>
<td align="right">55</td>
<td align="right">5</td>
</tr>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$447.4</td>
<td>$438.9</td>
<td>$442.72</td>
<td>$350.00</td>
<td>$44.2K</td>
<td align="right">12</td>
<td align="right">1</td>
</tr>
</tbody>
</table>

<h3>About Axon Enterprise</h3>
Axon Enterprise Inc is building a public safety operating system by integrating a suite of hardware devices and cloud software solutions. The company's suite includes cloud-hosted digital evidence management solutions, productivity and real-time operations software, body cameras, in-car cameras, TASER energy devices, drones and robotic security, and training solutions. The company's operation comprises of two operating segments, Software and Sensors, and TASER. The company generates the majority of its revenue from the Software and Sensors segment, which is engaged in developing, manufacturing, and selling fully integrated hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Having examined the options trading patterns of Axon Enterprise, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Axon Enterprise's Current Market Status</h3>
<ul>
<li>With a volume of 347,348, the price of AXON is up 0.76% at $785.96. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 61 days.</li>
</ul>
<h3>What Analysts Are Saying About Axon Enterprise</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $802.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Axon Enterprise, which currently sits at a price target of $895. 
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Axon Enterprise with a target price of $830. 
&#x2A; An analyst from Needham has decided to maintain their Buy rating on Axon Enterprise, which currently sits at a price target of $750. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Axon Enterprise, which currently sits at a price target of $735. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Axon Enterprise, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

AXON

Axon Enterprise's Options: A Look at What the Big Money is Thinking

Whales with a lot of money to spend have taken a noticeably bearish stance on Meta Platforms.
Looking at options history for Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) we detected 101 trades.
If we consider the specifics of each trade, it is accurate to state that 35% of the investors opened trades with bullish expectations and 37% with bearish.
From the overall spotted trades, 16 are puts, for a total amount of $829,423 and 85, calls, for a total amount of $9,211,257.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $5.0 to $820.0 for Meta Platforms over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Meta Platforms's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Meta Platforms's significant trades, within a strike price range of $5.0 to $820.0, over the past month.
<h3>Meta Platforms 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749150187_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>META</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$688.5</td>
<td>$684.55</td>
<td>$686.55</td>
<td>$5.00</td>
<td>$686.5K</td>
<td>7.1K</td>
<td align="right">65</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$687.4</td>
<td>$683.3</td>
<td>$685.35</td>
<td>$5.00</td>
<td>$479.7K</td>
<td>5.1K</td>
<td align="right">179</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$686.25</td>
<td>$682.35</td>
<td>$684.3</td>
<td>$5.00</td>
<td>$342.1K</td>
<td>5.1K</td>
<td align="right">739</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$31.3</td>
<td>$31.1</td>
<td>$31.1</td>
<td>$685.00</td>
<td>$311.0K</td>
<td>1.0K</td>
<td align="right">397</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/06/25</td>
<td>$389.15</td>
<td>$388.4</td>
<td>$389.15</td>
<td>$300.00</td>
<td>$233.4K</td>
<td>27</td>
<td align="right">56</td>
</tr>
</tbody>
</table>

<h3>About Meta Platforms</h3>
Meta is the largest social media company in the world, boasting close to 4 billion monthly active users worldwide. The firm's "Family of Apps," its core business, consists of Facebook, Instagram, Messenger, and WhatsApp. End users can leverage these applications for a variety of different purposes, from keeping in touch with friends to following celebrities and running digital businesses for free. Meta packages customer data, gleaned from its application ecosystem and sells ads to digital advertisers. While the firm has been investing heavily in its Reality Labs business, it remains a very small part of Meta's overall sales.
Having examined the options trading patterns of Meta Platforms, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Meta Platforms</h3>
<ul>
<li>With a trading volume of 7,832,019, the price of META is up by 0.09%, reaching $688.57.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 55 days from now.</li>
</ul>
<h3>Expert Opinions on Meta Platforms</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $811.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from JP Morgan persists with their Overweight rating on Meta Platforms, maintaining a target price of $735. 
&#x2A; Maintaining their stance, an analyst from Loop Capital continues to hold a Buy rating for Meta Platforms, targeting a price of $888. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Meta Platforms with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Check Out What Whales Are Doing With META

Financial giants have made a conspicuous bearish move on Docusign. Our analysis of options history for Docusign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) revealed 10 unusual trades.
Delving into the details, we found 40% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $189,569, and 5 were calls, valued at $318,449.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $85.0 to $100.0 for Docusign during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Docusign's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Docusign's significant trades, within a strike price range of $85.0 to $100.0, over the past month.
<h3>Docusign Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749150182_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DOCU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$14.05</td>
<td>$13.9</td>
<td>$14.03</td>
<td>$95.00</td>
<td>$130.4K</td>
<td>3.1K</td>
<td align="right">102</td>
</tr>
<tr>
<td>DOCU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$5.45</td>
<td>$5.4</td>
<td>$5.4</td>
<td>$93.00</td>
<td>$104.7K</td>
<td>83</td>
<td align="right">348</td>
</tr>
<tr>
<td>DOCU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/06/25</td>
<td>$2.74</td>
<td>$2.68</td>
<td>$2.68</td>
<td>$90.00</td>
<td>$53.3K</td>
<td>101</td>
<td align="right">184</td>
</tr>
<tr>
<td>DOCU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$3.3</td>
<td>$3.2</td>
<td>$3.25</td>
<td>$90.00</td>
<td>$44.2K</td>
<td>311</td>
<td align="right">178</td>
</tr>
<tr>
<td>DOCU</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/06/25</td>
<td>$3.95</td>
<td>$3.85</td>
<td>$3.9</td>
<td>$93.00</td>
<td>$39.0K</td>
<td>158</td>
<td align="right">128</td>
</tr>
</tbody>
</table>

<h3>About Docusign</h3>
Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in 2018.
Following our analysis of the options activities associated with Docusign, we pivot to a closer look at the company's own performance.
<h3>Current Position of Docusign</h3>
<ul>
<li>With a trading volume of 2,906,939, the price of DOCU is up by 0.38%, reaching $94.2.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 0 days from now.</li>
</ul>
<h3>What The Experts Say On Docusign</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $124.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from JMP Securities downgraded its action to Market Outperform with a price target of $124. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Docusign options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

DOCU

Check Out What Whales Are Doing With DOCU

Across the recent three months, 9 analysts have shared their insights on Udemy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UDMY#NASDAQ">UDMY</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $9.44, a high estimate of $12.00, and a low estimate of $7.00. A 12.43% drop is evident in the current average compared to the previous average price target of $10.78. 
<img src="https://www.benzinga.com/files/images/story/2025/1749150118_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Udemy by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Josh Baer</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$9.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Jason Tilchen</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Yi Fu Lee</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$9.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$11.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Noah Herman</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Josh Baer</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$7.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Terry Tillman</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$7.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Udemy. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Udemy compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Udemy's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Udemy's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/UDMY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Udemy analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Udemy: A Closer Look</h2>
Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Consumer and Enterprise, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.
<h3>Key Indicators: Udemy's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Udemy's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 1.75%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: Udemy's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -0.88%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Udemy's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -0.87%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Udemy's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.28%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Udemy's debt-to-equity ratio is below the industry average. With a ratio of 0.05, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 9 Analyst Ratings Have To Say About Udemy

Ratings for Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) were provided by 23 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">11</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Oracle, presenting an average target of $177.13, a high estimate of $220.00, and a low estimate of $130.00. This current average has decreased by 8.49% from the previous average price target of $193.57. 
<img src="https://www.benzinga.com/files/images/story/2025/1749150096_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Oracle among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Difucci</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$130.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$160.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$180.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>John Difucci</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Curtis Shauger</td>
<td>WestPark Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$195.00</td>
<td>-</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$190.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Brett Huff</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$167.00</td>
<td>-</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$194.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$170.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$175.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$150.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$135.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Jackson Ader</td>
<td>Keybanc</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$200.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Thomas Blakey</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$202.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$185.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$175.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$210.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Oracle. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Oracle compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Oracle's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Oracle's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ORCL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Oracle analyst ratings.</a>
<h2>Delving into Oracle's Background</h2>
Oracle provides enterprise applications and infrastructure offerings around the world through a variety of flexible IT deployment models, including on-premises, cloud-based, and hybrid. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system, which is commonly used for running online transaction processing and data warehousing workloads. Besides database systems, Oracle also sells enterprise resource planning, or ERP, customer relationship management, or CRM, and human capital management, or HCM, applications. Today, Oracle has more than 159,000 full-time employees in over 170 countries.
<h3>Oracle's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3M period, Oracle showcased positive performance, achieving a revenue growth rate of 6.4% as of 28 February, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Oracle's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 20.78%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Oracle's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 19.27%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Oracle's ROA excels beyond industry benchmarks, reaching 1.9%. This signifies efficient management of assets and strong financial health.
Debt Management: Oracle's debt-to-equity ratio surpasses industry norms, standing at 5.75. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ORCL

Where Oracle Stands With Analysts

Calvin Klein and Tommy Hilfiger parent&nbsp;PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) shares are trading lower after the company cut its FY25 guidance below estimates and issued second-quarter adjusted <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">EPS guidance below estimates</a>.
On Wednesday,&nbsp;PVH reported quarterly earnings of&nbsp;$2.30&nbsp;per share, which beat the analyst consensus estimate of&nbsp;$2.25.&nbsp;Quarterly revenue of $1.98 billion&nbsp;beat the <a target="_blank" href="https://www.benzinga.com/markets/earnings/25/06/45782126/calvin-klein-parent-pvh-stock-drops-after-q1-report-cut-full-year-outlook" rel="noreferrer noopener">Street estimate of&nbsp;$1.93 billion</a>.
The company cut its fiscal 2026 adjusted EPS guidance from a range of&nbsp;$12.40 to $12.75 to&nbsp;a new range of $10.75 to $11, versus <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">the&nbsp;$12.52&nbsp;analyst estimate</a>.
Telsey Advisory Group analyst Dana Telsey maintained an Outperform and $90&nbsp;price target.
The analyst writes that PVH posted a first-quarter beat, though its operating margin fell short due to gross margin pressures from an unfavorable channel mix and a promotional environment.
The analyst notes that the company reduced its FY25 earnings outlook, and the operating margin now includes incremental tariff pressure. 
Headwinds are expected to ease in the second half as the company offsets about half of the tariff impact with other strategic actions, adds the analyst.
Despite this challenging period, the analyst believes the business is building a stronger foundation for consumer engagement and marketplace execution in the long term.
Needham analyst Tom Nikic reiterated a Buy and $115&nbsp;price target.
The analyst writes that the company&#8217;s guidance cut will likely exert some selling pressure on the shares but believes the downward revision was largely already priced into the stock.
With revised numbers and an optically inexpensive valuation, Nikic still sees a favorable medium-term risk/reward, particularly due to underappreciated EPS drivers for 2026, such as GIII license takebacks, cost efficiencies, and share buybacks.
However, the analyst concedes that the &#8220;noisy&#8221; first-quarter earnings will likely temper investor enthusiasm in the near term.
Several analysts revised the price target and rating for the company <a href="https://www.benzinga.com/quote/PVH/analyst-ratings">following the results</a>:
Wells Fargo analyst Ike Boruchow kept an Equal-Weight rating and cut the price forecast from&nbsp;$100&nbsp;to&nbsp;$80.
BMO Capital analyst Simeon Siegel maintained a Market Perform rating and lowered the price forecast from&nbsp;$93&nbsp;to&nbsp;$84.
Evercore ISI Group analyst Michael Binetti reaffirmed an Outperform and trimmed the price forecast from&nbsp;$105&nbsp;to&nbsp;$95.
PVH Price Action: PVH shares are down 16.71% at $67.35&nbsp;at publication on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45787817/us-stocks-likely-to-open-on-a-mixed-note-after-dow-snaps-four-day-run-powell-and-the-fed-are-doing-the-right-thing-holding-rates-says-expert" target="_blank" rel="noreferrer noopener">US Stocks Likely To Open On A Mixed Note After Dow Snaps Four-Day Run: &#8216;Powell And The Fed Are Doing The Right Thing Holding Rates,&#8217; Says Expert</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Equities

Large Cap

Reiteration

Why Analyst Sees Attractive Valuation For Calvin Klein Parent PVH Despite 'Noisy' Q1

Analysts' ratings for Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) over the last quarter vary from bullish to bearish, as provided by 12 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $169.33, with a high estimate of $181.00 and a low estimate of $153.00. This current average has decreased by 0.44% from the previous average price target of $170.08. 
<img src="https://www.benzinga.com/files/images/story/2025/1749150069_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Johnson &amp; Johnson. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>David Risinger</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$153.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$165.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$164.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$169.00</td>
<td>$164.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$162.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$159.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$164.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Asad Haider</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$172.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Johnson &amp; Johnson. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Johnson &amp; Johnson compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Johnson &amp; Johnson's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Johnson &amp; Johnson's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JNJ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Johnson &amp; Johnson analyst ratings.</a>
<h2>Unveiling the Story Behind Johnson &amp; Johnson</h2>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
<h3>Johnson &amp; Johnson's Financial Performance</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Johnson &amp; Johnson's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 2.39%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Johnson &amp; Johnson's net margin is impressive, surpassing industry averages. With a net margin of 50.24%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Johnson &amp; Johnson's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 14.7%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Johnson &amp; Johnson's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.89% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Johnson &amp; Johnson's debt-to-equity ratio is below the industry average. With a ratio of 0.67, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

12 Analysts Have This To Say About Johnson & Johnson

Lowe's Companies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) short percent of float has risen 3.21% since its last report. The company recently reported that it has 9.01 million shares sold short, which is 1.61% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.66 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Lowe's Companies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749150052_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Lowe's Companies has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Lowe's Companies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Lowe's Companies's peer group average for short interest as a percentage of float is 4.63%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Lowe's Companies?

Press Releases

Applied Fundamental Research Issues Open Letter to FIGS Management and its Board of Directors

FIGS Announces Date of Fourth Quarter and Full Year 2024 Earnings Release, Conference Call and Webcast

FIGS Announces Participation in the Raymond James 46th Annual Institutional Investors Conference

Legal

Inari Medical, Figs Inc, Fastly, and Ryvyl Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

FIGS Releases Fourth Quarter and Full Year 2024 Financial Results

FIGS Adds Digital Marketing Executive Jerry Jao as New Independent Director to Its Board of Directors

FIGS Announces Date of First Quarter 2025 Earnings Release, Conference Call and Webcast

Jeffrey Lawrence Appointed Chairman of Joe & the Juice

FIGS Releases First Quarter 2025 Financial Results

FIGS Announces Participation in the Oppenheimer 25th Annual Consumer Growth and E-Commerce Conference

Comments

FIGS

Actualités

Dernières nouvelles pour FIGS (NYSE:FIGS) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL